SCHEMBL4964129

SCHEMBL4964129

CCNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1

nearest known ligand 0.75

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 19/20 0.75
CYP3A4 P08684 3/20 0.72
MAPKAPK2 P49137 3/20 0.72
PRKACA P17612 2/20 0.72
PRKACG P22612 2/20 0.72
PRKACB P22694 2/20 0.72
RPS6KB1 P23443 1/20 0.72
EGFR P00533 4/20 0.70
IKBKB O14920 1/20 0.70
MMP3 P08254 1/20 0.70
SRC P12931 1/20 0.70
PRKCA P17252 1/20 0.70
MAPK14 Q16539 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28773986 0.86 MAP3K8 (1.00) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL19713585 0.86 MAP3K8 (0.67) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL4961657 0.86 MAP3K8 (0.70) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL28770245 0.85 MAP3K8 (0.77) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL27728160 0.85 MAP3K8 (0.82) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL4962602 0.85 MAP3K8 (0.82) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL27728210 0.84 MAP3K8 (0.68) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL4964664 0.84 MAP3K8 (0.72) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL4960680 0.84 MAP3K8 (0.67) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG
SCHEMBL27707380 0.84 MAP3K8 (0.78) MAP3K8CYP3A4MAPKAPK2PRKACAPRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 MAP3K8 84/4885CYP3A4 2706/4885MAPKAPK2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.